BiBBInstruments announced that it is developing the first electric biopsy instrument, EndoDrill, with the ambition of facilitating and accelerating the diagnosis of some of the most serious cancer forms. The company's recent meetings with the FDA, following a market entry application, put EndoDrill on a clear regulatory pathway to US market access. A green light from the FDA would thus grant the company access to the large and most important market for EUS endoscopy.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.76 SEK | -0.83% | +1.49% | +50.63% |
May. 03 | BiBBInstruments AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 18 | BiBBInstruments Secures Patent for EndoDrill in India | MT |
1st Jan change | Capi. | |
---|---|---|
+50.63% | 11.67M | |
-12.09% | 19.25B | |
-39.00% | 2.96B | |
+22.02% | 1.96B | |
-0.62% | 1.69B | |
+33.51% | 1.27B | |
-16.17% | 982M | |
-22.01% | 913M | |
+5.38% | 801M | |
-23.80% | 630M |
- Stock Market
- Equities
- BIBB Stock
- News BiBBInstruments AB
- BiBBInstruments Aims for US Market Entry in 2023